video: This video footage of a nanopipette extracting a sample from a single cell was taken in 2011, when the device was being developed. A video of the process used in this new research would look different but this is helpful in demonstrating the “nanobiopsy” procedure.
Credit: Dr Paolo Actis
The high-tech double-barrel nanopipette, developed by University of Leeds scientists, and applied to the global medical challenge of cancer, has - for the first time - enabled researchers to see how individual living cancer cells react to treatment and change over time – providing vital understanding that could help doctors develop more effective cancer medication.
The tool has two nanoscopic needles, meaning it can simultaneously inject and extract a sample from the same cell, expanding its potential uses. And the platform’s high level of semi-automation has sped up the process dramatically, enabling scientists to extract data from many more individual cells, with far greater accuracy and efficiency than previously possible, the study shows.
Currently, techniques for studying single cells usually destroy them, meaning a cell can be studied either before treatment, or after.
This device can take a “biopsy” of a living cell repeatedly during exposure to cancer treatment, sampling tiny extracts of its contents without killing it, enabling scientists to observe its reaction over time.
During the study, the multi-disciplinary team, featuring biologists and engineers, tested cancer cells’ resistance to chemotherapy and radiotherapy using glioblastoma (GBM) - the deadliest form of brain tumour - as a test case, because of its ability to adapt to treatment and survive.
Their findings are published today (7pm GMT/2pm ET, Wednesday, March 6) in the journal Science Advances.
Significant breakthrough
One of the paper’s corresponding authors, Dr Lucy Stead, Associate Professor of Brain Cancer Biology in the University of Leeds’ School of Medicine, said: “This is a significant breakthrough. It is the first time that we have a technology where we can actually monitor the changes taking place after treatment, rather than just assume them.
“This type of technology is going to provide a layer of understanding that we have simply never had before. And that new understanding and insight will lead to new weapons in our armoury against all types of cancer.”
She added: “GBM is the cancer in most need of those new weapons because in 20 years there has been no improvement in survival in this disease.
“It is lagging behind so much and we think that is because of the highly ‘plastic’ nature of these tumours – their ability to adapt to treatment and survive it.
“That is why it is so important that we can dynamically observe and characterise these cells as they change, so we can map out the journey these cells can take, and subsequently find ways to stop them at every turn. We simply couldn’t do that with the technologies that we had.”
Transformative
Dr Stead leads the Glioma Genomics research group at the Leeds Institute of Medical Research at St James's Hospital, which is focused on trying to cure GBM brain tumours. She added: “This technology could be transformative for this particular cancer, helping us finally identify effective treatments for this awful, incurable disease.”
The research was primarily funded by The Brain Tumour Charity, which counts former Leeds footballer Dominic Matteo as one of its high-profile supporters. Matteo did not have GBM but underwent surgery to remove a brain tumour in 2019.
Dr Simon Newman, Chief Scientific Officer at The Brain Tumour Charity, said: “We know glioblastoma cells respond differently to treatment, often developing treatment resistance which leads to recurrence. The development of this novel technology, which can extract samples from tumour cells grown in the lab before and after treatment, will give a unique insight into how drug resistance may develop and lead to tumours growing back.
“We hope that this important work, funded by The Brain Tumour Charity, will improve our knowledge of these complex brain tumours and allow us to find new, more effective treatments – something so urgently needed for those faced with this devastating disease.”
Collaborative
The study was a collaboration between researchers from Leeds’ Bragg Centre for Materials Research; Leeds’ School of Electronic and Electrical Engineering; Leeds Institute of Medical Research, and the Earlham Institute, Norwich, who studied single GBM cells over a period of 72hrs.
They used the nanosurgical platform, which is far too small to be manipulated by hand. The miniscule needles are precisely controlled by robotic software to manoeuvre them into position, into the cells in the petri dish. The nanopipette’s second needle plays a fundamental role in controlling the equipment.
The device allows scientists to take samples repeatedly, to study the progression of disease in an individual cell. Much research on molecular biology is carried out on populations of cells, giving an average result that ignores the fact that every cell is different.
Some cells die during treatment, but others survive. The key to finding a cure is understanding what allows one cell to survive and what is happening to the ones that die.
Unprecedented precision
Lead author Dr Fabio Marcuccio, Research Associate in the Faculty of Medicine at Imperial College London, who carried out the research while at Leeds, said: “Our device allows the study of the way brain cancer cells adapt to treatment over time, with unprecedented precision. This tool will provide data that could lead to significant improvements in cancer treatment and prognoses.”
He added: “This work is the result of a collaborative effort with my colleagues and co-leads Dr Chalmers Chau, Research Fellow in Bionanotechnology in Leeds’ School of Electronic and Electrical Engineering, and Dr Georgette Tanner, formerly of Leeds, now Bioinformatician at Oxford Nanopore Technologies, whose contributions were fundamental to the experimental design and data analysis. This demonstrates the importance of creating an interdisciplinary team to tackle the biggest challenges of our time.”
Cancer cell plasticity - the ability of cells to change their behaviours - is one of the biggest challenges in cancer treatment as it remains poorly understood. GBM cancer cells are particularly “plastic”: they can adapt very quickly, and this is thought to help them develop resistance to radiotherapy and chemotherapy. Learning how these cells adapt, and subsequently how we can block them, could prevent cancer from recurring, something which almost always happens with GBM.
Camilla Hawkins, an occupational therapist from London, was diagnosed with GBM in August 2022. The 55-year-old said: “Any findings, such as these, that could help inform new treatments, has got to be welcomed. Extended good quality of life is worth living, even where the prognosis is terminal.”
Crucially important
The other corresponding author and co-lead Dr Paolo Actis, Associate Professor of Bio-Nanotechnology in Leeds’ School of Electronic and Electrical Engineering, has been working on the nanobiopsy tool for around 15 years and said its new capabilities, compared to its original scope, provided “remarkable advantages”.
He added: “Cancer cells that are not killed by chemotherapy are the ones that make the cancer grow back and lead to death.
“Our tool can pinpoint these cells and we can now perform biopsies on them so we can specifically study how the ones that survive treatment have changed.
“This is crucially important as the more we can understand how the cells change, the more drugs we can develop to stop them from adapting.”
Dr Stead said further research needed to be carried out, using this technology on many more samples in the lab and in humans, but that it had already yielded hugely valuable information.
Additional funding was provided by UK Research and Innovation and the European Commission.
Case Study (with photos)
Camilla’s Story
Camilla Hawkins was diagnosed with a multi-focal glioblastoma multiforme brain tumour in August 2022.
The occupational therapist, from London, called her GP service for advice after struggling to find the right words in a work meeting.
At first, medics thought she may have suffered a stroke, and after speaking to a trainee GP, who advised she visit her local Emergency Department, she was admitted to a stroke ward. Three weeks of investigations followed, before she learned her diagnosis. Understandably, the news came as a huge shock.
The 55-year-old parkrun enthusiast and volunteer, who ran the London Marathon in support of The Brain Tumour Charity last year, says: “I went overnight from being a fit and active occupational therapist to an inpatient, eventually diagnosed with an incurable brain tumour with a limited life expectancy.
“I had worked in oncology many years ago, and in HIV for over 25 years, so I was aware of the statistics that one in two people will be diagnosed with cancer in their lifetime.
“However, the possibility that I might have a brain tumour had literally not entered my head (no pun intended!) I had even commented to the Stroke Consultant, ‘at least it’s not a brain tumour!’
“This type of tumour is always stage 4, and there is no cure.
“There is so little research for this condition, and the lack of research means that many people – myself included – look to other ways in which we might control our cancer. All sorts of things are suggested as possibilities on patient forums and on the web, but none of these are supported by evidence, so medical professionals cannot comment on them.
“I understand that with a patient cohort all of whom will be terminal, research is going to be challenging, but any findings, such as these, that could help inform new treatments, has got to be welcomed. Extended good quality of life is worth living, even where the prognosis is terminal.”
Further Information
Embargoed: Not for Release Until 2pm U.S. Eastern Time Wednesday, 06 March 2024.
The paper “Single-cell nanobiopsy enables multigenerational longitudinal transcriptomics of cancer cells”
DOI: 10.1126/sciadv.adl0515 will appear in the March 6, 2024, issue of the journal Science Advances, published by AAAS, the science society, the world's largest general scientific society. See https://www.science.org/, and https://www.aaas.org/
More information, including a copy of the paper, can be found online at the Science Advances press package at https://www.eurekalert.org/press/vancepak/
Reporters having difficulty accessing the paper from the press package, please contact vancepak@aaas.org
Email University of Leeds press officer Deb Newman on d.newman@leeds.ac.uk with any further media enquiries, to speak to the researchers, or to request an interview with Camilla.
Funding: This research was funded by The Brain Tumour Charity, with additional funding from UKRI and the European Commission.
University of Leeds
The University of Leeds is one of the largest higher education institutions in the UK, with more than 39,000 students from about 170 different countries. We are renowned globally for the quality of our teaching and research.
We are a values-driven university, and we harness our expertise in research and education to help shape a better future for humanity, working through collaboration to tackle inequalities, achieve societal impact and drive change.
The University is a member of the Russell Group of research-intensive universities, and is a major partner in the Alan Turing, Rosalind Franklin and Royce Institutes www.leeds.ac.uk
Follow University of Leeds or tag us into coverage: Twitter | Facebook | LinkedIn | Instagram
Imperial College London
Imperial College London is a global top ten university with a world-class reputation. Imperial’s 22,000 students and 8,000 staff are working to solve the biggest challenges in science, medicine, engineering and business.
Imperial ranks sixth in the 2024 QS World University Rankings and eighth in the 2024 Times Higher Education World University Rankings. The 2021 Research Excellence Framework (REF) found that it has a greater proportion of world-leading research than any other UK university. It also received a Gold Award in the 2023 Teaching Excellence Framework (TEF). Imperial was named University of the Year in the Daily Mail University Guide 2024, University of the Year for Graduate Employment in The Times and Sunday Times Good University Guide 2024 and awarded a Queen’s Anniversary Prize for its COVID-19 response. https://www.imperial.ac.uk/
Earlham Institute, Norwich
The Earlham Institute is a hub of life science research, training, and innovation focused on understanding the natural world through the lens of genomics. Embracing the full breadth of life on Earth, our scientists specialise in developing and testing the latest tools and approaches needed to decode living systems and make predictions about biology. The Earlham Institute is based within the Norwich Research Park and is one of eight institutes that receive strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC), part of UKRI, as well as support from other research funders.
The Brain Tumour Charity
The Brain Tumour Charity is the UK’s largest dedicated brain tumour charity, committed to fighting brain tumours on all fronts. It funds pioneering research to increase survival and improve treatment options as well as raise awareness of the symptoms and effects of brain tumours to bring about earlier diagnosis. The Charity also provides support for everyone affected by a diagnosis that they can live as full a life as possible, with the best quality of life. Find out more: https://www.thebraintumourcharity.org/
ENDS
Journal
Science Advances
Method of Research
Experimental study
Subject of Research
Cells
Article Title
Single-cell nanobiopsy enables multigenerational longitudinal transcriptomics of cancer cells
Article Publication Date
6-Mar-2024
COI Statement
N/A